COPD

Overview

COPD is the dominant chronic respiratory disease worldwide. In 2017, 544.9 million people had a chronic respiratory disease, chronic respiratory diseases were the third leading cause of death (7.0% of all deaths), and most of that death and disability burden was due to COPD.^[4] Smoking was the leading risk factor for chronic respiratory disease-related disability in men across all regions.^[4] Almost all of this burden passes through general practice: diagnosis, cessation, inhaler therapy, exacerbation management and end-of-life planning are primary-care work.

The natural history frames every intervention. FEV1 falls gradually over a lifetime, but in susceptible smokers it falls faster; smoking causes irreversible obstructive changes, and stopping smoking does not restore lost lung function — it reverts the rate of further loss to normal.^[3] That is why cessation is the only disease-modifying intervention in COPD, and why it belongs in every consultation with every patient who smokes.

References27ShowHide

1. [1]Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J, 2023.PMID 36858443
2. [2]Mangione CM, Barry MJ, Nicholson WK, et al. Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA, 2022.PMID 35536260
3. [3]Fletcher C, Peto R The natural history of chronic airflow obstruction. Br Med J, 1977.PMID 871704
4. [4]GBD Chronic Respiratory Disease Collaborators Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med, 2020.PMID 32526187
5. [5]Wang Z, Qiu Y, Ji X, Dong L Effects of smoking cessation on individuals with COPD: a systematic review and meta-analysis. Front Public Health, 2024.PMID 39722704
6. [6]Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 2016.PMID 27158893
7. [7]Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet, 2016.PMID 27116918
8. [8]Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev, 2018.PMID 29852054
9. [9]Cahill K, Stevens S, Perera R, Lancaster T Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev, 2013.PMID 23728690
10. [10]Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med, 2018.PMID 29668352
11. [11]Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med, 2020.PMID 32579807
12. [12]Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med, 2016.PMID 27181606
13. [13]Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med, 2014.PMID 25196117
14. [14]Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med, 2016.PMID 27066739
15. [15]Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, et al. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res, 2020.PMID 32943047
16. [16]Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 1987.PMID 3492164
17. [17]Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA, 2013.PMID 23695200
18. [18]Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2017.PMID 28702957
19. [19]Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011.PMID 21864166
20. [20]McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2015.PMID 25705944
21. [21]Walters JA, Tang JN, Poole P, Wood-Baker R Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2017.PMID 28116747
22. [22]Yudhawati R, Aini FN, Wicaksono NF A Systematic Review and Meta-Analysis of Immunogenicity and Safety of the Influenza Vaccine in COPD Patients, and Its Relevance with Real-World Effectiveness. Int J Chron Obstruct Pulmon Dis, 2026.PMID 41939928
23. [23]Schrijver J, Lenferink A, Brusse-Keizer M, Zwerink M, van der Valk PD, et al. Self-management interventions for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2022.PMID 35001366
24. [24]Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med, 2003.PMID 12759479
25. [25]Sehdai YR, Awan H, Roy P, Chowdhury F, Siddiq A, et al. Endobronchial Zephyr valves for bronchoscopic lung volume reduction for severe emphysema: a systematic review and meta-analysis. Ann Med Surg (Lond), 2025.PMID 40851937
26. [26]Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α(1)-antitrypsin deficiency. Eur Respir J, 2017.PMID 29191952
27. [27]McDonald CF, Crockett AJ, Young IH Adult domiciliary oxygen therapy. Position statement of the Thoracic Society of Australia and New Zealand. Med J Aust, 2005.PMID 15963018